title: High-Density Lipoprotein Mimetics: a Therapeutic Tool for Atherosclerotic Diseases.
abstract: Clinical trials and epidemiological studies have revealed a negative correlation between serum high-density lipoprotein (HDL) cholesterol levels and the risk of cardiovascular events. Currently, statin treatment is the standard therapy for cardiovascular diseases, reducing plasma low-density lipoprotein (LDL) cholesterol levels. However, more than half of the patients have not been able to receive the beneficial effects of this treatment.The reverse cholesterol transport pathway has several potential anti-atherogenic properties. An important approach to HDL-targeted therapy is the optimization of HDL cholesterol levels and function in the blood to enhance the removal of circulating cholesterol and to prevent or mitigate inflammation that causes atherosclerosis. Cholesteryl ester transfer protein inhibitors increase HDL cholesterol levels in humans, but whether they reduce the risk of atherosclerotic diseases is unknown. HDL therapies using HDL mimetics, including reconstituted HDL, apolipoprotein (Apo) A-IMilano, ApoA-I mimetic peptides, or full-length ApoA-I, are highly effective in animal models. In particular, the Fukuoka University ApoA-I-mimetic peptide (FAMP) effectively removes cholesterol via the ABCA1 transporter and acts as an anti-atherosclerotic agent by enhancing the biological functions of HDL without elevating HDL cholesterol levels.Our literature review suggests that HDL mimetics have significant atheroprotective potential and are a therapeutic tool for atherosclerotic diseases.
authors.affiliation: Faculty of Sports and Health Science, Fukuoka University.
authors.forename: Masahiro
authors.initials: M
authors.lastname: Ikenaga
authors.forename: Yasuki
authors.initials: Y
authors.lastname: Higaki
authors.forename: Keijiro
authors.initials: K
authors.lastname: Saku
authors.forename: Yoshinari
authors.initials: Y
authors.lastname: Uehara
mesh_terms: D064286:ATP Binding Cassette Transporter 1 / Q000378:metabolism; D000818:Animals; D016632:Apolipoprotein A-I / Q000494:pharmacology; D050197:Atherosclerosis / Q000097:blood / Q000628:therapy*; D002784:Cholesterol / Q000378:metabolism; D008076:Cholesterol, HDL / Q000097:blood* / Q000737:chemistry; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D008075:Lipoproteins, HDL / Q000494:pharmacology*; D051379:Mice; D010455:Peptides / Q000494:pharmacology; D010743:Phospholipids / Q000494:pharmacology; D011994:Recombinant Proteins / Q000494:pharmacology
chemical_list: C577836:ABCA1 protein, human; C505693:APOA1 protein, human; D064286:ATP Binding Cassette Transporter 1; D016632:Apolipoprotein A-I; C000591544:CER-001; D008076:Cholesterol, HDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008075:Lipoproteins, HDL; D010455:Peptides; D010743:Phospholipids; D011994:Recombinant Proteins; D002784:Cholesterol